Details of the Drug Combination

General Information of Drug Combination (ID: DC7OYWQ)

• Drug Combination Name: LAROPIPRANT + Vitamin B3
• Indication: Dyslipidemia; Status: Discontinued [1]
• Component Drugs:
  LAROPIPRANT (DM5FABJ): Small molecular drug
  Vitamin B3 (DMQVRZH): Small molecular drug

Molecular Interaction Atlas of This Drug Combination

Indication(s) of LAROPIPRANT

Disease Entry	ICD 11	Status	REF
Coronary heart disease	BA80.Z	Phase 4	[2]
Arteriosclerosis	BD40	Discontinued in Phase 3	[3]

LAROPIPRANT Interacts with 7 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Prostaglandin E2 receptor EP2 (PTGER2)	TT1ZAVI	PE2R2_HUMAN	Inhibitor	[14]
HMG-CoA reductase (HMGCR)	TTPADOQ	HMDH_HUMAN	Inhibitor	[15]
Prostaglandin D2 receptor 2 (PTGDR2)	TTQDMX5	PD2R2_HUMAN	Inhibitor	[14]
Prostaglandin D2 receptor (PTGDR)	TTNVEIR	PD2R_HUMAN	Inhibitor	[14]
Prostaglandin F2-alpha receptor (PTGFR)	TTT2ZAR	PF2R_HUMAN	Inhibitor	[14]
Thromboxane A2 receptor (TBXA2R)	TT2O84V	TA2R_HUMAN	Inhibitor	[14]
Prostacyclin receptor (PTGIR)	TTOFYT1	PI2R_HUMAN	Inhibitor	[14]

LAROPIPRANT Interacts with 2 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cytochrome P450 2C9 (CYP2C9)	OTGLBN29	CP2C9_HUMAN	Increases Metabolism	[13]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Increases Metabolism	[13]

Indication(s) of Vitamin B3

Disease Entry	ICD 11	Status	REF
Chronic renal failure	GB61.Z	Approved	[4]
Hypercholesterolaemia	5C80.0	Approved	[5]
Hyperlipidemia	5C80.Z	Approved	[6]
Hyperlipidemia, familial combined, LPL related	N.A.	Approved	[7]
Hypertriglyceridemia	5C80.1	Approved	[8]
Lipid metabolism disorder	5C52.Z	Approved	[9]
Primary hypercholesterolemia	5C80.00	Approved	[10]
Psoriasis	EA90	Approved	[11]
Vitamin deficiency	5B55-5B71	Approved	[12]

Vitamin B3 Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Nicotinic acid receptor (HCAR2)	TTWNV8U	HCAR2_HUMAN	Agonist	[9]
Diacylglycerol O-acyltransferase 2 (DGAT2)	TTRHEQ4	DGAT2_HUMAN	Inhibitor	[9]

Vitamin B3 Interacts with 1 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cyclic ADP-ribose hydrolase 1 (CD38)	DEGF70S	CD38_HUMAN	Metabolism	[17]

Vitamin B3 Interacts with 32 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Long-chain fatty acid transport protein 2 (SLC27A2)	OT7JEG5F	S27A2_HUMAN	Increases Expression	[18]
Phospholipid-transporting ATPase ABCA1 (ABCA1)	OT94G6BQ	ABCA1_HUMAN	Increases Expression	[19]
Apolipoprotein A-I (APOA1)	OT5THARI	APOA1_HUMAN	Increases Expression	[20]
C-reactive protein (CRP)	OT0RFT8F	CRP_HUMAN	Decreases Expression	[21]
Apolipoprotein B-100 (APOB)	OTH0UOCZ	APOB_HUMAN	Decreases Expression	[20]
Intercellular adhesion molecule 1 (ICAM1)	OTTOIX77	ICAM1_HUMAN	Decreases Expression	[22]
ATP synthase subunit beta, mitochondrial (ATP5F1B)	OTLFZUQK	ATPB_HUMAN	Decreases Expression	[23]
Apolipoprotein(a) (LPA)	OTRZLU9F	APOA_HUMAN	Decreases Expression	[24]
C-C motif chemokine 2 (CCL2)	OTAD2HEL	CCL2_HUMAN	Decreases Expression	[25]
Platelet endothelial cell adhesion molecule (PECAM1)	OTXOM4D9	PECA1_HUMAN	Decreases Expression	[22]
Platelet glycoprotein 4 (CD36)	OT5CZWKY	CD36_HUMAN	Increases Expression	[18]
Carnitine O-palmitoyltransferase 2, mitochondrial (CPT2)	OTIN6G20	CPT2_HUMAN	Decreases Expression	[26]
Proteinase-activated receptor 1 (F2R)	OT4WVWBO	PAR1_HUMAN	Increases Expression	[16]
Peroxisome proliferator-activated receptor gamma (PPARG)	OTHMARHO	PPARG_HUMAN	Increases Expression	[19]
Leptin (LEP)	OT5Q7ODW	LEP_HUMAN	Increases Expression	[27]
Hydroxycarboxylic acid receptor 3 (HCAR3)	OTJBHLX0	HCAR3_HUMAN	Increases Expression	[18]
Fatty acid synthase (FASN)	OTFII9KG	FAS_HUMAN	Decreases Expression	[26]
CCAAT/enhancer-binding protein alpha (CEBPA)	OTOM9OE4	CEBPA_HUMAN	Increases Expression	[26]
CCAAT/enhancer-binding protein delta (CEBPD)	OTNBIPMY	CEBPD_HUMAN	Increases Expression	[26]
5'-AMP-activated protein kinase catalytic subunit alpha-2 (PRKAA2)	OTU1KZPV	AAPK2_HUMAN	Increases Activity	[28]
Hormone-sensitive lipase (LIPE)	OTMMVJ8A	LIPS_HUMAN	Decreases Expression	[26]
Peroxisome proliferator-activated receptor alpha (PPARA)	OTK095PP	PPARA_HUMAN	Increases Expression	[29]
Platelet-activating factor acetylhydrolase (PLA2G7)	OT6H6AMO	PAFA_HUMAN	Decreases Expression	[21]
Oxysterols receptor LXR-alpha (NR1H3)	OT54YZ9I	NR1H3_HUMAN	Increases Expression	[19]
Adiponectin (ADIPOQ)	OTNX23LE	ADIPO_HUMAN	Increases Expression	[26]
Long-chain fatty acid transport protein 4 (SLC27A4)	OTWT4HAF	S27A4_HUMAN	Increases Expression	[18]
NAD-dependent protein deacetylase sirtuin-2 (SIRT2)	OT5Q6SVK	SIR2_HUMAN	Increases Expression	[30]
Scavenger receptor class B member 1 (SCARB1)	OTAE1UA1	SCRB1_HUMAN	Increases Expression	[19]
Diacylglycerol O-acyltransferase 2 (DGAT2)	OTE5PDD0	DGAT2_HUMAN	Decreases Activity	[31]
Resistin (RETN)	OTW5Z1NH	RETN_HUMAN	Decreases Expression	[32]
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1A)	OTHCDQ22	PRGC1_HUMAN	Increases Expression	[33]
NAD-dependent protein lipoamidase sirtuin-4, mitochondrial (SIRT4)	OT5S0J23	SIR4_HUMAN	Increases Expression	[30]

References

• [1] ClinicalTrials.gov (NCT01054508) Effect of Tredaptive on Serum Lipoproteins and Inflammatory Markers. U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT01126073) A Double Blind, Randomized Study to Compare Influence of Niacin/Laropiprant on Functional and Morphological Characteristics of Arterial Wall and Parameters of Inflammation in Subjects With Coronary Heart Disease Already Treated With a Statin in Miran Sebestjen, University Medical Centre Ljubljana.
• [3] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023729)
• [4] Nicotinamide for photoprotection and skin cancer chemoprevention: A review of efficacy and safety. Exp Dermatol. 2019 Feb;28 Suppl 1:15-22.
• [5] Vitamin B3 impairs reverse cholesterol transport in Apolipoprotein E-deficient mice. Clin Investig Arterioscler. 2019 Nov-Dec;31(6):251-260.
• [6] Vitamin B3. 2024 Feb 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 JanC.
• [7] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [8] Niacin: chemical forms, bioavailability, and health effects. Nutr Rev. 2012 Jun;70(6):357-66.
• [9] Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE: The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002 Jul;147(1):20-31.
• [10] Extended-release niacin (nicotinic acid)/laropiprant. Drugs. 2009 Aug 20;69(12):1665-79.
• [11] Cosmeceutical Aptitudes of Niacinamide: A Review. Recent Adv Antiinfect Drug Discov. 2021;16(3):196-208.
• [12] Hydrosoluble vitamins. Handb Clin Neurol. 2014;120:891-914.
• [13] Metabolism of MK-0524, a prostaglandin D2 receptor 1 antagonist, in microsomes and hepatocytes from preclinical species and humans. Drug Metab Dispos. 2007 Feb;35(2):283-92. doi: 10.1124/dmd.106.011551. Epub 2006 Nov 28.
• [14] Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
• [15] A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
• [16] The in vitro effects of niacin on platelet biomarkers in human volunteers. Thromb Haemost. 2010 Aug;104(2):311-7. doi: 10.1160/TH10-01-0015. Epub 2010 Jun 10.
• [17] ADP-ribosyl cyclase and CD38 catalyze the synthesis of a calcium-mobilizing metabolite from NADP. J Biol Chem. 1995 Dec 22;270(51):30327-33.
• [18] Structure-dependent effects of pyridine derivatives on mechanisms of intestinal fatty acid uptake: regulation of nicotinic acid receptor and fatty acid transporter expression. J Nutr Biochem. 2014 Jul;25(7):750-7. doi: 10.1016/j.jnutbio.2014.03.002. Epub 2014 Mar 22.
• [19] Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol. 2004 Feb 1;67(3):411-9. doi: 10.1016/j.bcp.2003.09.014.
• [20] Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol. 2001 Nov;21(11):1783-9. doi: 10.1161/hq1001.096624.
• [21] Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol. 2006 Sep 15;98(6):743-5. doi: 10.1016/j.amjcard.2006.04.011. Epub 2006 Jul 26.
• [22] Effects of niacin on cell adhesion and early atherogenesis: biochemical and functional findings in endothelial cells. Basic Clin Pharmacol Toxicol. 2009 Mar;104(3):206-10. doi: 10.1111/j.1742-7843.2008.00364.x. Epub 2009 Jan 21.
• [23] Niacin inhibits surface expression of ATP synthase beta chain in HepG2 cells: implications for raising HDL. J Lipid Res. 2008 Jun;49(6):1195-201. doi: 10.1194/jlr.M700426-JLR200. Epub 2008 Mar 3.
• [24] Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes. Diabetes Obes Metab. 2002 Jul;4(4):255-61. doi: 10.1046/j.1463-1326.2002.00205.x.
• [25] Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis. 2009 Jan;202(1):68-75. doi: 10.1016/j.atherosclerosis.2008.04.044. Epub 2008 May 9.
• [26] Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance. Atherosclerosis. 2009 Jul;205(1):207-13. doi: 10.1016/j.atherosclerosis.2008.11.026. Epub 2008 Dec 3.
• [27] Extended-release niacin raises adiponectin and leptin. Atherosclerosis. 2007 Aug;193(2):361-5. doi: 10.1016/j.atherosclerosis.2006.06.028. Epub 2006 Aug 2.
• [28] Reduced plasma FFA availability increases net triacylglycerol degradation, but not GPAT or HSL activity, in human skeletal muscle. Am J Physiol Endocrinol Metab. 2004 Jul;287(1):E120-7. doi: 10.1152/ajpendo.00542.2003. Epub 2004 Jan 28.
• [29] Effects of niacin and chromium on the expression of ATP-binding cassette transporter A1 and apolipoprotein A-1 genes in HepG2 cells. J Nutr Biochem. 2009 Apr;20(4):261-8. doi: 10.1016/j.jnutbio.2008.02.010. Epub 2008 Jul 7.
• [30] Effects of niacin restriction on sirtuin and PARP responses to photodamage in human skin. PLoS One. 2012;7(7):e42276. doi: 10.1371/journal.pone.0042276. Epub 2012 Jul 31.
• [31] Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res. 2004 Oct;45(10):1835-45. doi: 10.1194/jlr.M300403-JLR200. Epub 2004 Jul 16.
• [32] Adipokines and treatment with niacin. Metabolism. 2006 Oct;55(10):1283-5. doi: 10.1016/j.metabol.2006.07.002.
• [33] A cardiac-specific robotized cellular assay identified families of human ligands as inducers of PGC-1 expression and mitochondrial biogenesis. PLoS One. 2012;7(10):e46753. doi: 10.1371/journal.pone.0046753. Epub 2012 Oct 3.